Abstract
Background: As policy responses to cannabis use and availability change internationally, levels of cannabis use disorder rise and treatment seeking increases. Diversion to cannabis treatment from the criminal justice system also increases demand in the system. At a time of developing treatment systems in response to this demand, an understanding of the evidence is increasingly important.
Objective: To provide a narrative review of the developing evidence-base for psycho-social interventions for cannabis use disorder, including adjunctive cannabinoid agonist therapy. Method: Two researchers independently conducted a literature search for articles published prior to February 2016, located through online search of four electronic databases (Google Scholar, CINAHL, Medline, and PsycINFO). Only randomised controlled trials describing treatment(s) for cannabis use or cannabis use disorder with a measure of either cannabis use frequency or cannabis use disorder severity were included. Non-English papers, review papers, posters, opinion pieces, letters or editorials, case studies (N<10) and published abstracts were excluded. Results: The cannabis treatment most likely to be effective for adolescents and adults is based on the combination of Motivational Enhancement Therapy (MET) and Cognitive Behavioural Therapy (CBT) with the inclusion of contingency management and agonist replacement therapy showing promise. Conclusion: A more concrete and robust evidence base is required for these interventions. Replication of treatment studies is needed using standardised interventions, methods and measures to minimise conflicting findings, inconsistent follow-up periods and relatively poor treatment effects over time.Keywords: Marijuana, addiction, interventions, cognitive behavioural therapy, agonist replacement.
Current Pharmaceutical Design
Title:A Narrative Review of Psychological Cannabis Use Treatments with And Without Pharmaceutical Adjunct
Volume: 22 Issue: 42
Author(s): Jan Copeland, Peter Gates and Izabella Pokorski
Affiliation:
Keywords: Marijuana, addiction, interventions, cognitive behavioural therapy, agonist replacement.
Abstract: Background: As policy responses to cannabis use and availability change internationally, levels of cannabis use disorder rise and treatment seeking increases. Diversion to cannabis treatment from the criminal justice system also increases demand in the system. At a time of developing treatment systems in response to this demand, an understanding of the evidence is increasingly important.
Objective: To provide a narrative review of the developing evidence-base for psycho-social interventions for cannabis use disorder, including adjunctive cannabinoid agonist therapy. Method: Two researchers independently conducted a literature search for articles published prior to February 2016, located through online search of four electronic databases (Google Scholar, CINAHL, Medline, and PsycINFO). Only randomised controlled trials describing treatment(s) for cannabis use or cannabis use disorder with a measure of either cannabis use frequency or cannabis use disorder severity were included. Non-English papers, review papers, posters, opinion pieces, letters or editorials, case studies (N<10) and published abstracts were excluded. Results: The cannabis treatment most likely to be effective for adolescents and adults is based on the combination of Motivational Enhancement Therapy (MET) and Cognitive Behavioural Therapy (CBT) with the inclusion of contingency management and agonist replacement therapy showing promise. Conclusion: A more concrete and robust evidence base is required for these interventions. Replication of treatment studies is needed using standardised interventions, methods and measures to minimise conflicting findings, inconsistent follow-up periods and relatively poor treatment effects over time.Export Options
About this article
Cite this article as:
Copeland Jan, Gates Peter and Pokorski Izabella, A Narrative Review of Psychological Cannabis Use Treatments with And Without Pharmaceutical Adjunct, Current Pharmaceutical Design 2016; 22 (42) . https://dx.doi.org/10.2174/1381612822666160831094811
DOI https://dx.doi.org/10.2174/1381612822666160831094811 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Evaluating the Risk of Covid-19 Transmission from Conjunctival and Lacrimal Discharge: A Review
Current Biotechnology Recent Advances in the Treatment of Helicobacter pylori Infection
Recent Patents on Anti-Infective Drug Discovery New Perspectives on Acetaminophen
Current Cardiology Reviews Early Age of Migraine Onset is Independently Related to Cognitive Decline and Symptoms of Depression Affect Quality of Life
Current Neurovascular Research Neurokinin-1 Receptor Antagonists in Lung Cancer Therapy
Letters in Drug Design & Discovery A Review on the Nutritional Aspects of Wild Edible Plants
Current Traditional Medicine Novel Options for the Pharmacological Treatment of Chronic Anal Fissure – Role of Botulin Toxin
Current Clinical Pharmacology Seasonal and Perennial Allergic Conjunctivitis
Recent Patents on Inflammation & Allergy Drug Discovery Recent Advances in 5-HT1B / 1D Receptor Antagonists and Agonists and their Potential Therapeutic Applications
Current Topics in Medicinal Chemistry Withdrawal Notice: Evaluation of Clinical Profile, Diagnostic Tests, And Prognosis of Crypto-coccal Meningitis in HIV Infected Patients in Western India
Infectious Disorders - Drug Targets GABAB Receptors-Associated Proteins: Potential Drug Targets in Neurological Disorders?
Current Drug Targets The Alcohol Hangover Research Group Consensus Statement on Best Practice in Alcohol Hangover Research
Current Drug Abuse Reviews The Applications of Pharmacogenomics to Neurological Disorders
Current Molecular Medicine West Nile Virus Vaccine.
Current Drug Targets - Infectious Disorders Efficacy and Cardiovascular Safety of DPP-4 Inhibitors
Current Drug Safety C-Abl Inhibition; A Novel Therapeutic Target for Parkinson's Disease
CNS & Neurological Disorders - Drug Targets Psychiatric Disorders Associated with FXTAS
Current Psychiatry Reviews Azathioprine in Multiple Sclerosis
Mini-Reviews in Medicinal Chemistry Myelin Sheaths and Autoimmune Response Induced by Myelin Proteins and Alphaviruses. I. Physicochemical Background
Current Medicinal Chemistry The Role of Venous Abnormalities in Neurological Disease
Reviews on Recent Clinical Trials